Zidovudine inhibits hepatitis B virus replication.
Hepatitis B virus DNA polymerase is a viral enzyme that can use viral DNA as well as viral RNA as a template for DNA synthesis. Since both activities are essential for the production of new virus particles, blocking of this enzyme should reduce viral replication. In the present study the in vitro effect of zidovudine triphosphate on hepatitis B virus DNA polymerase activity and the in vivo effect of zidovudine on viral replication in chronic HBsAg-positive patients are investigated. Zidovudine triphosphate inhibited in vitro DNA polymerase activity by 50% at a concentration of 0.3 microM. Serum DNA polymerase activity was significantly reduced in 7 patients who received zidovudine (200 mg orally 4 times daily) for one week. A dose-response effect was suggested by the results found for 6 patients who received 100 mg, 200 mg and 300 mg orally 4 times daily for one week with 2 drug-free weeks between each course. We conclude that zidovudine may be of value for non-responders to alpha-interferon therapy or patients with high initial levels of viral replication prior to the start of interferon treatment.
Berk
L
L
Department of Internal Medicine II, University Hospital Dijkzigt, Rotterdam, The Netherlands.
Schalm
S W
SW
Heijtink
R A
RA
D000284:Administration, Oral; D006509:Hepatitis B / Q000188:drug therapy / Q000382:microbiology; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D009426:Netherlands; D019384:Nucleic Acid Synthesis Inhibitors; D013942:Thymine Nucleotides / Q000037:antagonists & inhibitors; D014779:Virus Replication / Q000187:drug effects*; D015215:Zidovudine / Q000008:administration & dosage / Q000494:pharmacology*
D019384:Nucleic Acid Synthesis Inhibitors; D013942:Thymine Nucleotides; D015215:Zidovudine; C024157:thymidine 5'-triphosphate